secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001104659-24-132308
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 1.01, 5.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO raises $10.75M in private placement; cash runway into Q1 2026
----------------------------------------------------------------------

- Gross proceeds of $10.75M from 1,340,603 common shares at $6.44 and 3,286 Series I preferred shares at $644.
- Series I preferred convertible into 100 common shares per share; beneficial ownership limitation of 9.99% (up to 19.99%).
- Cash resources, including proceeds, expected to fund operations into Q1 2026; net proceeds to advance KPI-012 for PCED.
- Phase 2b CHASE trial enrollment over 80% complete; topline data expected Q2 2025.
- Participation from new and existing investors including SR One, Cormorant, Woodline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/0001104659-24-132308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/tm2432193d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-132308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer